Abstracts tagged "COVID-19"

Abstract Number: 0747 • ACR Convergence 2022
Methotrexate and Hydroxychloroquine Used as Single Agent May Diminish Breakthrough Infection After COVID-19 Vaccination
Haihui Wang¹ and Andras Perl², ¹Upstate Medical University, Fayetteville, NY, ²SUNY, Syracuse, NY
Background/Purpose: Immunosuppressive medications generally predispose patients to greater risk of serious complications upon COVID-19 infection. This study was initiated to assess whether individual drugs may…
Abstract Number: 0783 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases
Md Yuzaiful Md Yusof¹, Jack Arnold², Benazir Saleem³, Claire Vandevelde³, Shouvik Dass³, Sinisa Savic¹, Edward M Vital¹ and Paul Emery¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³Rheumatology Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: There are concerns regarding the safety of rituximab (RTX) during the COVID-19 pandemic due its effect on humoral immunity. Data from registries during pre-vaccination…
Abstract Number: 0799 • ACR Convergence 2022
Serum Laboratory Parameters of Hemophagocytic Lymphohistiocytosis Syndrome in Patients with Autoimmune Rheumatic Diseases Infected with SARS-CoV-2: A Retrospective Comparative Study
Omar Alsaed, Samar Al emadi, Karima Becetti, Eman Satti, Hadil Ashour, Yousef Alrimawi, Miral H.Gharib, Mohamad Alkahlout, Rawan Saleh, Basem Awadh and Mohammed Hammoudeh, Hamad Medical Corporation, Doha, Qatar
Background/Purpose: The serum features of the cytokine storm induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are similar to those of hemophagocytic lymphohistiocytosis…
Abstract Number: 1194 • ACR Convergence 2022
Key Self-reported Determinants of COVID-19 Vaccine Acceptance Among Persons with and Without Autoimmune Disease
Jenny Gong¹, Emma Barnboym², megan O'Mara³, Natalie Gurevich³, Maya Mattar⁴, Donald Anthony⁵, Adam Perzynski² and Nora Singer⁶, ¹Case Western School of Medicine, Cleveland, OH, ²The MetroHealth System, Cleveland, OH, ³Cleveland Veteran Affairs Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁵Case, VA, Metro, Chardon, OH, ⁶The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Patients with autoimmune disease are at increased risk for complications from SARS-CoV-2 infection. We aimed to compare patient perspectives on COVID-19 vaccination among persons…
Abstract Number: 1392 • ACR Convergence 2022
Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic
Maria Mirza¹, Kaiyang Song¹, Madiha Ashraf², Anushka Soni³, John Jackman³ and Raashid Luqmani¹, ¹Oxford University Hospital, Oxford, United Kingdom, ²Oxford Universtiy Hospital, Oxford, United Kingdom, ³Oxford University Hospital, Oxford, England, United Kingdom
Background/Purpose: During the COVID-19 pandemic, asynchronous consultations were introduced due to the significant backlog of patients with Rheumatoid arthritis awaiting clinical review. PROMs including Self-Reported…
Abstract Number: 1821 • ACR Convergence 2022
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Jasvinder singh¹, Timothy Bergquist², Vithal Madhira³ and Alfred Anzalone⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sage Bionetworks, Seattle, WA, ³Palila Software, L.L.C., Reno, NV, ⁴University of Nebraska Medical Center, Ohama, NE
Background/Purpose: To examine whether the use of colchicine and other gout medications is associated with the risk of COVID-19 infection, hospitalization, and subsequent outcomes in…
Abstract Number: 2081 • ACR Convergence 2022
COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
Amit Saxena¹, Alexis Engel², Brittany Banbury¹, Ghadeer Hasan³, Nicola Fraser¹, Devyn Zaminski¹, Mala Masson⁴, Rebecca Haberman⁵, Jose Scher², Gary Ho⁶, Jammie Law³, Paula Rackoff¹, Chung-E Tseng⁵, H Michael Belmont¹, Robert Clancy¹, Jill Buyon⁷ and Peter Izmirly⁷, ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone, New York, NY, ⁴NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk for severe disease from COVID-19 and decreased vaccine efficacy, due to inherent immune perturbations…
Abstract Number: 0108 • ACR Convergence 2022
Study of the Level of Antibody Response to COVID-19 Vaccine in a Minority Population with Rheumatological Disorders
Tanushree Bhatt, Snigdha Gadireddy, Pravash Budhathoki and Giovanni Franchin, Bronxcare Health System, Bronx, NY
Background/Purpose: Multiple studies have shown reduced immunogenicity of mRNA covid vaccines in patients with rheumatological disease. The waning antibody levels in this population group, whether…
Abstract Number: 0440 • ACR Convergence 2022
COVID-19 in Patients with ANCA Associated Vasculitis – Single Center Experience
Alojzija Hocevar¹, Matija Tomšič² and Ziga Rotar¹, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²UMC Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: In patients with ANCA associated vasculitis (AAV) a higher mortality rate due to COVID-19 has been observed compared to general population. We aimed to…
Abstract Number: 0748 • ACR Convergence 2022
Mapping Long COVID-19 Patient Journeys for Rheumatic Disease Patients
Yomei Shaw¹, Beth Wallace², Hallie Chabrier³, Charlotte Cochrane³, Christina Kim³, Katherine Taylor³, Armaan Patel³, Nima Keyvan⁴, Vinayak Swaroop³, Nina Nguyen³, Sara Hustek⁵, Meriah Moore⁴, Andrew Admon⁴ and Kaleb Michaud⁶, ¹FORWARD, The National Databank for Rheumatic Diseases, Santa Fe, NM, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Michigan Division of Rheumatology, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan Division of Rheumatology, Mount Clemens, MI, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: One-third of individuals who contract COVID-19 develop 'long COVID' symptoms that persist after their initial illness. Long COVID can cause fatigue, chronic pain, and…
Abstract Number: 0784 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
Cassandra Calabrese¹, Elizabeth Kirchner², M. Elaine Husni³, Brandon Moss², Anthony Fernandez², Yuxuan Jin³ and Leonard Calabrese³, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Immunocompromised patients with immune mediated inflammatory diseases (IMIDs) undergoing therapy with B cell depleting agents (BCDT) are among the most vulnerable to severe COVID-19…
Abstract Number: 0817 • ACR Convergence 2022
Predictive Severity Factors of COVID-19 in Patients with Rheumatic Immune Mediated Diseases
David Martínez-López¹, Ivan Ferraz Amaro², Diana Prieto-Peña³, Fabricio Benavides Villanueva¹, Cristina Corrales¹, Lara Sánchez-Bilbao¹, Alba Herrero-Morant⁴, Carmen Alvarez Reguera¹, martín Trigueros-Vazquez¹, Reinhard Wallmann⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco⁷, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ⁵Servicio Cántabro de Salud, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: COVID-19 has become a common disease in patients with rheumatic immune-mediated diseases (R-IMID). A risk stratification of the patients at COVID-19 onset is important…
Abstract Number: 1197 • ACR Convergence 2022
Folic Acid and Methotrexate Use and Their Association with COVID-19 Diagnosis and Mortality: An Analysis from the UK Biobank
Ruth Topless¹, Ralph Green², Sarah L Morgan³, Philip Robinson⁴, Tony Merriman¹ and Angelo Gaffo³, ¹University of Otago, Dunedin, New Zealand, ²Departments of Pathology and Medicine, University of California Davis at Sacramento, Sacramento, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴School of Clinical Medicine, University of Queensland, Brisbane, Australia
Background/Purpose: Folate metabolism is implicated in SARS-CoV-2 infectivity. The current study seeks to determine if methotrexate (an antifolate) or folic acid prescription were associated with…
Abstract Number: 1489 • ACR Convergence 2022
Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis
Devy Zisman¹, Noa Hayat¹, Amir Haddad², Joy Feld³, Tal Gazitt¹, Idit Lavi¹, Ilan feldhamer⁴, ARNON DOV COHEN⁴ and Walid Saliba¹, ¹Carmel Medical Center, Haifa, Israel, ²Carmel Medical Centre, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Clalit Health Services, Tel Aviv, Israel
Background/Purpose: The importance and efficacy of anti COVID-19 vaccine in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: 1857 • ACR Convergence 2022
Increasing Proportion of MDA-5 Associated Conditions in a Tertiary Myositis Centre Following Onset of the Covid-19 Pandemic
Jennifer Hannah¹, Saadia Sasha Ali¹, Sloni Arora¹, John Cazabon¹, James Galloway¹ and Patrick Gordon², ¹King's College London, London, United Kingdom, ²King’s College Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Anti-MDA5 dermatomyositis is a clinical subtype of DM that is strongly associated with a rapidly progressive phenotype of interstitial lung disease resulting in a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].